Dr. Joanne B. Weidhaas, MD

Dr. Weidhaas practices at Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health.

Dr. Weidhaas' NPI, 1295723294, was assigned on October 12, 2005. Dr. Weidhaas graduated from Tufts University School Of Medicine in 1999. Dr. Weidhaas' Connecticut license number on file is 042328.

Dr. Weidhaas' primary practice is Ronald Reagan UCLA Medical Center, at 757 Westwood Plaza, Los Angeles, CA 90095 in Los Angeles County. The practice phone is (310) 825-6301.

Dr. Weidhaas' primary practice is Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health. The medical group on file is UCLA Radiation Oncology.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Weidhaas practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Weidhaas' primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Weidhaas is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Weidhaas' licenses on file in 3 states: Connecticut, California and New York.

Dmand AI lists bone cancer radiation and breast cancer radiation among the conditions Dr. Weidhaas treats.

CMS data shows 159 Medicare services from Dr. Weidhaas across 6 procedure codes in 2024, for 38 Medicare patients. Medicare paid $11,749 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 38 Medicare patients who saw Dr. Weidhaas in 2024. The largest group is 65 to 74, with 20 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 1.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Weidhaas' median patient age at 65, with 99% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. Weidhaas for performance year 2024, reported as part of a group. Dr. Weidhaas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Weidhaas as offering telehealth.

Dmand AI links 60 papers to Dr. Weidhaas, published from 2006 to 2022. 2011 was the busiest year, with 5. The most frequent topics are MicroRNAs, Breast Neoplasms and Proto-Oncogene Proteins p21(ras). Dr. Weidhaas has published most often in Cell Cycle. Dr. Weidhaas' most frequent co-authors are Rachel C. Blitzblau, MD, PhD, Adam P. Dicker, MD and Anuja Jhingran, MD.

Dmand AI links Dr. Weidhaas to 4 clinical trials. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Endometriosis. Yale University sponsors the most, 2.

CMS Open Payments shows 20 general payments to Dr. Weidhaas from 5 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 64% of the total. AstraZeneca Pharmaceuticals LP paid the most, $6,028.

Dmand AI lists 8 awards for Dr. Weidhaas, most recently Michael Fry Research Award in 2009.

Dr. Weidhaas graduated from Tufts University School Of Medicine in 1999.

Dr. Weidhaas is in network with 12 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.